Detection, evaluation, and treatment of severe and resistant hypertension Proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, MD, USA, October 10th 2013

Journal of the American Society of Hypertension

Volumn 8, Issue 10, 2014, Pages 743-757

  White, William B ^a   Rick Turner, J ^b   Sica, Domenic A ^c   Bisognano, John D ^d   Calhoun, David A ^e   Townsend, Raymond R ^f   Aronow, Herbert D ^g   Bhatt, Deepak L ^h   Bakris, George L ⁱ  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b IQVIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Saint Joseph Mercy Health System   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Complex drug therapy; Device therapy for hypertension; Renal denervation; Treatment resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CAROTID ARTERY BARORECEPTOR ACTIVATION THERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL STUDY; DEVICE THERAPY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; HEALTH INSURANCE; HUMAN; KIDNEY DENERVATION; MEDICAL DEVICE; MEDICAL SOCIETY; METHODOLOGY; PRIORITY JOURNAL; RESISTANT HYPERTENSION; TREATMENT REFUSAL; ULTRASOUND; ADOLESCENT; ADULT; AGED; DRUG RESISTANCE; HYPERTENSION; MIDDLE AGED; ORGANIZATION; PATIENT COMPLIANCE; UNITED STATES;

ADOLESCENT; ADULT; AGED; CONGRESSES AS TOPIC; DRUG RESISTANCE; HUMANS; HYPERTENSION; MIDDLE AGED; PATIENT COMPLIANCE; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84910621680     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.06.005     Document Type: Review

References (88)

1. Kumbhani DJ, Steg G, Cannon CP, Eagle KA, Smith CS Jr, Crowley K, et al; on behalf of the REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013;34:1204-14.
2. Gulati V, White WB. Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens 2013;7:484-93.
3. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al; for the Symplicity HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension.NEngl JMed 2014;370:1393-401.
4. Uppuluri SC, Storozynsky E, Bisognano JD. Baroreflex device therapy in the treatment of hypertension. Curr Hypertens Rep 2009;11:69-75.
5. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 2011;57:880-6.
6. Alnima T, de Leeuw PW, Kroon AA. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract 2012; 2012:587194.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
9. Mancia G, De Backer G, Dominiczak A, kova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
11. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. Updated ESH position paper on interventional therapy of resistant hypertension. Euro Intervention 2013;9(Suppl R):R58-66.
12. Elliott WJ. High prevalence of white-coat hypertension in Spanish resistant hypertensive patients. Hypertension 2011;57:889-90.
13. Turner JR, O'Brien E. Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2013;15:868-73.
14. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
15. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-58.
16. Grigoryan L, Pavlik VN, Hyman DJ. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. J Am Soc Hypertens 2013;7: 471-6.
17. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013; 62:691-7.
18. Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D, et al. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens 2014; 32:415-22.
19. Kleman M, Dhanyamraju S, DiFilippo W. Prevalence and characteristics of pseudohypertension in patients with "resistant hypertension". J Am Soc Hypertens 2013;7:467-70.
20. Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens 2013; 7:509-11.
21. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens 2009;27:280-6.
22. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med 2013;159:185-94.
23. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al; on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension Position Paper on ambulatory blood pressure monitoring. J Hy-pertens 2013;31:1731-68.
24. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hy-pertens 2012;30:874-6.
25. Campese VM. Interventional hypertension: a new hope or a new hype? The need to redefine resistant hypertension. J Hypertens 2013;31:2118-22.
26. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report. Heart 2013;99:1579-87.
27. Grassi G, Bobbelli M, Seravalle G, Brambilla G, Dell'oro R, Mancia G. Role of ambulatory blood pressure monitoring in resistant hypertension. Curr Hyper-tens Rep 2011;15(3):232-7.
28. Mahfoud F, Lüscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, et al; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34:2149-57.
29. Schlaich MP, Schmieder RE, Bakris G, jn PJ, Böhm M, Campese VM, et al. International Expert Consensus Statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. JCAA 2013; 62:2013-45.
30. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension 2013;62:982-7.
31. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011;8:686-93.
32. National Institute for Health and Care Excellence. Clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. August 2011. Available at: http://guidance.nice.org.uk/CG127/Guidance (Accessed 1st May 2014).
33. Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation 2007;115:2091-3.
34. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012;60:34-42.
35. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004;22:435-45.
36. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013;128: 132-40.
37. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, et al. Divergent results using clinical and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010;56: 824-30.
38. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension 2012;60:310-8.
39. Wang JG, Sun NL, Ke YN, Zhang BH, Ikegami N, Zhu JR. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements. Clin Drug Investig 2012;32:729-34.
40. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010;4:42-50
41. [Erratum: JAm Soc Hypertens 2010;4:99].
42. Mann SJ. Drug therapy for resistant hypertension: a simplified, mechanistic approach. J Clin Hypertens (Greenwich) 2011;12:120-30.
43. Mann SJ, Parikh NS. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich) 2012;14:191-7.
44. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991; 151: 1786-92.
45. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR; RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18(5 Pt 1):619-26.
46. Turner JR. Patient and physician adherence in hypertension management. J Clin Hypertens (Greenwich) 2013;15:447-52.
47. Spence JD. Physiologic tailoring of treatment in resistant hypertension. Curr Cardiol Rev 2010;6: 119-23.
48. Elliott WJ, Egan B, Giles TD, Bakris GL, White WB, Sansone TM. Rationale for establishing a mechanism to increase reimbursement to hypertension specialist. J Clin Hypertens 2013; 15:397-403.
49. Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014;39:171-82.
50. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-33.
51. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010;55:147-52.
52. Baker WL, White WB. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012;46:889-94.
53. Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980-90.
54. Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F Administration-time-dependent effects of blood pressure-lowering medications: basis for the chro-notherapy of hypertension. Blood Press Monit 2010;15: 173-80.
55. Deeks ED. Olmesartan medoxomil/amlodipine/hydro-chlorothiazide: fixed-dose combination in hypertension. Drugs 2011;71:209-20.
56. Petry NM, Rash CJ, Byrne S, Ashraf S, White WB. Financial reinforcers for improving medication adherence: findings from a meta-analysis. Am J Med 2012; 125:888-96.
57. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013;62:218-25.
58. Ledur PS, Leiria LF, Severo MD, Silveira DT, Massierer D, Becker AD, et al. Perception of uncontrolled blood pressure and non-adherence to anti-hypertensive agents in diabetic hypertensive patients. JAm Soc Hyper-tens 2013;7:477-83.
59. Howren MB. Adherence. In: Gellman MD, Turner JR, editors. Encyclopedia of Behavioral Medicine. New York: Springer; 2013. P. 33-9.
60. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihy-pertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014;100:855-61.
61. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;CD000011.
62. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012;157:785-95.
63. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessmentofserum antihyper-tensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011;34:87-90.
64. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hyper-tens 2013;31:766-74.
65. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013;62:526-32.
66. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012;33:1058-66.
67. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens 2012;21:46-51.
68. Mancia G, Grassi G. The central sympathetic nervous system in hypertension. Handb Clin Neurol 2013;117: 329-35.
69. Evelyn KA, Alexander F, Cooper SR. Effect of sympa-thectomy on blood pressure in hypertension: a review of 13 years' experience of the Massachusetts General Hospital. JAMA 1949;140:592-602.
70. Smithwick RH, Bush RD, Kinsey D, Whitelaw GP. Hypertension and associated cardiovascular disease; comparison of male and female mortality rates and their influence on selection of therapy. JAMA 1956; 160:1023-6.
71. Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg 1941;114:753-75.
72. Smithwick RH. Surgery in hypertension. Lancet 1948; 2:65.
73. Grimson KS, Orgain ES, Anderson B, Broome RA, Longino FH. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglio-nectomy. Ann Surg 1949;129:850-71.
74. Martin EA, Victor RG. Premise, promise, and potential limitations of invasive devices to treat hypertension. Curr Cardiol Rep 2011;13:86-92.
75. Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baror-eflex activation: past, present, and future. Curr Hyper-tens Rep 2010;12:61-6.
76. Bisognano JD, Bakris G, Nadim MK, chez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58:765-73.
77. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P; DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011;57:1787-8.
78. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012;6: 152-8.
79. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baror-eflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012;6: 270-6.
80. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multi-centre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
81. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-7.
82. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9.
83. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013;34:2132-40.
84. REDUCE-HTN trial (annual meeting of Transcatheter Cardiovascular Therapeutics (TCT) (TCT, San Francisco, October 2013.
85. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, et al. Renal denervation in moderate treatment resistant hypertension. J Am Coll Cardiol 2013; 62:1880-6.
86. Böhm M, Mahfoud F, Ukena C, Bauer A, Fleck E, Hoppe UC, et al. Rationale and design of a large registry on renal denervation: the Global SYMPLIC-ITY registry. Euro Intervention 2013;9:484-92.
87. Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre-and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J 2013;34:2141-8. 2148b.
88. Dawood O, Gertner M, Brinton T. Ultrasonic renal dener-vation in severe hypertension (annual meeting of the Cardiovascular Research Technology (CRT), Washington, D.C. February 25, 2014.